BTIG Research Initiates Teva Pharmaceutical At Buy

Analysts at BTIG Research initiated coverage on Teva Pharmaceutical Industries Ltd (ADR) TEVA with a Buy rating. The target price for Teva Pharmaceutical is set to $77. Teva Pharmaceutical shares have gained 15.77 percent over the past 52 weeks, while the S&P 500 index has surged 5.35 percent in the same period. Teva Pharmaceutical's shares rose 0.60 percent to $62.01 in after-hours trading.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: InitiationAnalyst RatingsBTIG Research
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!